| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
InMode Ltd.$15.28
+0.27 (+1.8%)
F 10Pipeline Score MedTech · Clinical
Market Cap
870.55 M
EPS
1.38
P/E Ratio
10.07 $
Value Trade
9.82 M
-2.48 %
Week
-6.02 %
1 Month
-7.85 %
3 Month
-0.15 %
6 Month
-66.07 %
5 Year
103.56 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
823.38 K
52 Week Range
12.72 - 16.74
% held by Insiders
14.82 %
% held by Institutions
57.19 %
Enterprise Value
338.22 M
Total Shares
63.38 M
Short %
5.28 %
Float Shares
55.77 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 840 of 912)
Percentile RankInMode Ltd. has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INMD▲ +10.8%on this news
InMode Confirms Receipt of Unsolicited Proposal
InMode Ltd. announced that its Board received an unsolicited acquisition proposal from MN Business Strategy, offering $16.20 per share. A special committee of independent directors has been formed to evaluate the proposal. The company has not committed to any specific outcome or timeline regarding the proposal.
Read more →INMDInMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
InMode Ltd. has appointed Dr. Shlomo Nass as the new Chairman of the Board and Moshik Itzkovich as Chief Financial Officer. Dr. Nass succeeds Dr. Michael Anghel, who recently retired, while Itzkovich takes over from Yair Malca. Both appointments are expected to enhance the company's governance and financial strategies.
Read more →INMDInMode to Present at Upcoming Investor Conferences and Events
InMode Ltd. announced its participation in upcoming investor conferences, including a virtual bus trip and an in-person fireside chat at the Jefferies Global Healthcare Conference. Presenters will include Yair Malca, the outgoing CFO, and Moshik Itzkovich, Senior VP of Finance. The events aim to engage investors and discuss InMode's innovative medical technologies.
Read more →INMD▼ -5.6%on this news
InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
InMode Ltd. reported its financial results for the first quarter of 2026, showing a 5% increase in GAAP revenue to $82 million compared to the previous year. However, the company experienced a decline in net income and operating margins. The firm maintains a strong cash position and has initiated a share repurchase program, signaling confidence in its future performance despite macroeconomic challenges.
Read more →INMDInMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
InMode Ltd. has announced its expectations for the first quarter of 2026 financial results, projecting revenue between $81.5 million and $81.7 million. The company also anticipates a non-GAAP gross margin of 75% to 76%. Furthermore, InMode has reiterated its full-year revenue guidance for 2026, estimating between $365 million and $375 million. A conference call is scheduled for May 6, 2026, to discuss these results.
Read more →INMDInMode to Present at the 25th Annual Needham Virtual Healthcare Conference
InMode Ltd. announced its participation in the 25th Annual Needham Virtual Healthcare Conference, where CEO Moshe Mizrahy and CFO Yair Malca will present. The presentation is scheduled for April 13, 2026, and will be moderated by Michael Matson. Additionally, InMode will conduct virtual one-on-one investor meetings on the same day.
Read more →INMD▲ +6.1%on this news
InMode Announces New Share Repurchase Program InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized...
InMode Ltd. has announced a new share repurchase program, allowing the company to buy back approximately 10% of its outstanding shares, totaling around 6.38 million shares. The decision comes after the company successfully repurchased $127.4 million in shares in 2025. InMode aims to utilize its strong cash flow for these repurchases while continuing to assess future capital allocation opportunities.
Read more →INMD▼ -6.7%on this news
InMode Announces Conclusion of Independent Transaction Committee Review InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the...
InMode Ltd. has concluded its independent transaction committee review, determining that none of the proposals received were adequate for the company's interests. The committee has decided to discontinue the review process and will focus on evaluating its business and growth strategies. No additional updates will be shared unless deemed necessary.
Read more →INMDInMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd. reported its fourth quarter and full year 2025 financial results, showing a quarterly revenue increase of 6% to $103.9 million, while full year revenue decreased by 6% to $370.5 million. The company highlighted a strong cash position and plans to launch new products in 2026. Despite challenges in the industry, early signs of stabilization were noted, particularly in Europe.
Read more →INMDInMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer...
InMode Ltd. announced its participation in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference. CFO Yair Malca will host investor meetings on February 11, 2026, in Snowbird, Utah. Interested investors can schedule meetings through BTIG sales representatives.
Read more →INMD▲ +5.8%on this newsshared move
InMode Responds to Transaction Rumors InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies ("InMode" or the "Company"), today issued the following...
InMode Ltd. has acknowledged recent market rumors about a non-binding acquisition proposal by Steel Partners Holdings L.P. The company is currently reviewing strategic alternatives through a committee of independent directors. While they have retained legal and financial advisors, there is no guarantee of a transaction or outcome from this review process.
Read more →INMD▼ -8.8%on this news
InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. anticipates releasing its financial results for Q4 and full year 2025 on February 10, 2026. Preliminary estimates suggest Q4 revenue will range from $103.6 million to $103.8 million, with full year revenue expected between $370.2 million and $370.4 million. The company will hold a conference call to discuss these results, featuring key executives.
Read more →INMDInMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins InMode Ltd. (NASDAQ: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd. reported its third quarter 2025 financial results, showing a revenue of $93.2 million, down from $130.2 million in the same quarter of 2024. The company experienced a 26% increase in revenues from consumables and services, but overall net income fell significantly. Management remains optimistic despite challenging economic conditions and has appointed a new President for North America.
Read more →INMDInMode Appoints Michael Dennison as President of North America InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice...
InMode Ltd. has appointed Michael Dennison as President of North America, promoting him from Vice President of Sales. Dennison brings nearly a decade of experience at InMode and a strong background in the aesthetic medical device industry. His leadership is expected to drive revenue growth and strengthen the company's market position in North America.
Read more →INMDInMode to Participate in Upcoming Investor Conferences InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor ...
InMode Ltd. has announced its participation in several upcoming investor conferences in November 2025. Key presentations will be made by CFO Yair Malca and CEO Moshe Mizrahy at events including the UBS Global Healthcare Conference and Jefferies Global Healthcare Conference. These conferences will provide opportunities for one-on-one meetings and discussions about InMode's innovative medical technologies.
Read more →INMD▲ +5.6%on this news
InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. announced its upcoming financial results for Q3 2025, expecting revenue between $92.5 million and $93.0 million. The company will hold a conference call on November 5, 2025, to discuss these results. Additionally, InMode reiterated its full-year revenue guidance for 2025, maintaining a range of $365 million to $375 million.
Read more →INMDInMode to Present at Baird 2025 Global Healthcare Conference InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer...
InMode Ltd. announced that CFO Yair Malca will present at the Baird 2025 Global Healthcare Conference on September 10, 2025. The presentation will include a fireside chat moderated by Jeff Johnson, and InMode will also conduct one-on-one investor meetings. The company is recognized for its innovative medical technologies utilizing RF technology.
Read more →INMDInMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd. reported its second quarter 2025 financial results, showing a revenue increase to $95.6 million compared to $86.4 million in Q2 2024. The company maintained strong gross margins of 80%, although revenues from consumables and services declined by 6%. Management highlighted ongoing macroeconomic challenges but noted record international sales, particularly in Europe.
Read more →INMDInMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. plans to release its Q2 2025 financial results on July 30, 2025. The company anticipates revenue for the quarter to be between $95.4 million and $95.5 million, with a non-GAAP gross margin of 79% to 80%. However, it has lowered its full-year revenue guidance due to ongoing market challenges.
Read more →INMDInMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025 InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital...
InMode Ltd. CEO Moshe Mizrahy responded to DOMA Perpetual Capital's concerns regarding the company's buyback program, production capacity, and sales organization. He emphasized the company's commitment to shareholder value and timely product delivery despite challenges. Mizrahy defended his leadership against criticisms and reiterated the importance of maintaining operations in Israel.
Read more →INMDInMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of...
InMode Ltd. has received Health Canada certification for its IgniteRF platform, which features advanced radiofrequency technologies, including the new QuantumRF. This platform allows for minimally invasive procedures with minimal downtime, catering to the growing demand for effective aesthetic treatments. CEO Moshe Mizrahy emphasized the importance of this launch in expanding InMode's global footprint.
Read more →INMDInMode to Present at Upcoming Investor Conferences and Events InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor ...
InMode Ltd. announced its participation in several upcoming investor conferences, including the BNP 3rd Annual Aesthetics Day, Barclays West Coast Bus Trip, and Jefferies Global Healthcare Conference. Key executives will present in various formats, including virtual fireside chats and in-person meetings. This engagement aims to enhance investor relations and showcase InMode's innovative medical technologies.
Read more →INMDInMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District ...
InMode Ltd. has been granted a permanent injunction by the US District Court against sellers of counterfeit Morpheus8 devices. The court's ruling includes damages awarded to InMode and aims to protect the company's trademark rights and consumer safety. InMode's CEO emphasized the company's commitment to combating counterfeit goods and ensuring public safety.
Read more →INMD▼ -12.1%on this news
InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd. reported its first quarter 2025 financial results, showing a 3% decrease in revenue to $77.9 million compared to the same quarter in 2024. The company experienced a decline in revenues from consumables and services, alongside a decrease in operating margins. Despite these challenges, InMode highlighted strong international performance, particularly in Europe, and a solid cash position of $512.9 million.
Read more →INMDInMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. announced it will release its Q1 2025 financial results on April 28, 2025. The company expects revenues for the quarter to be between $77.2 million and $77.5 million, with a gross margin of 78% to 79%. Additionally, InMode reiterated its full-year revenue guidance for 2025, projecting between $395 million and $405 million.
Read more →INMDInMode to Present at the 24th Annual Needham Virtual Healthcare Conference InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive...
InMode Ltd. will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. CEO Moshe Mizrahy and CFO Yair Malca will participate in a fireside chat moderated by Michael Matson. The company will also hold one-on-one investor meetings on the same day.
Read more →INMDInMode Responds to Doma Perpetual's Letters InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital...
InMode Ltd. addressed concerns raised by DOMA Perpetual Capital regarding its capital allocation and operational management. The company refuted claims about inefficiencies in returning capital to shareholders and emphasized its ongoing buy-back program. InMode also highlighted its commitment to R&D and strategic management changes while dismissing the need for additional legal actions.
Read more →INMDInMode to Present at Upcoming Investor Conferences InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor ...
InMode Ltd. announced its participation in two upcoming investor conferences in March 2025. The Barclays 27th Annual Global Healthcare Conference will feature CFO Yair Malca, while the Oppenheimer 34th Annual Healthcare MedTech & Services Conference will include CEO Moshe Mizrahy and CFO Yair Malca. Both events will provide opportunities for investor engagement through presentations and one-on-one meetings.
Read more →INMDInMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd. reported its financial results for Q4 and full year 2024, revealing a 23% decrease in quarterly revenues and a 20% decline in annual revenues. Despite these challenges, the company returned $285.4 million to shareholders and has a strong cash position. A new share repurchase program has been approved, reflecting management's confidence in future growth.
Read more →INMDInMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its...
InMode Ltd. has rescheduled its fourth quarter and full year 2024 earnings conference call to February 4, 2025, at 8:30 a.m. EST, earlier than previously planned. The company will release its financial results before the market opens on the same day. Key management will present during the call, and participants are encouraged to pre-register.
Read more →INMD▼ -8%on this news
InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. (Nasdaq: INMD) announced it will release its financial results for Q4 and full year 2024 on February 6, 2025. Preliminary results indicate expected revenue between $97.0 million and $97.5 million for Q4, with full-year revenue projected at $394.0 million to $394.5 million. The company will hold a conference call to discuss these results, which will also be available via webcast.
Read more →INMDInMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024) InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...
InMode Ltd. reported its third quarter 2024 financial results, showing a GAAP revenue of $130.2 million, which includes $31.9 million from pre-orders. Despite a decrease in consumables revenue and a downward revision of annual revenue guidance, the company achieved a net income of $51 million, reflecting a positive trend compared to the previous year. Management noted ongoing challenges due to macroeconomic conditions but expressed confidence in operational adjustments.
Read more →INMDInMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has been granted a preliminary injunction by the U.S....
InMode Ltd. has been granted a preliminary injunction by the U.S. District Court against sellers of counterfeit Morpheus8 devices. The court's decision, issued on September 3, 2024, also included a Temporary Restraining Order to protect InMode's trademarks. The company emphasizes its commitment to public safety and plans to continue pursuing enforcement against counterfeit products.
Read more →INMDMorpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, is pleased to announce an additional FDA 510(k) clearance...
InMode Ltd. has announced that its Morpheus8 technology has received FDA 510(k) clearance for soft tissue contraction, making it the first of its kind in fractional radiofrequency microneedling. This clearance expands its existing FDA approval and coincides with the launch of new platforms, IgniteRF and OptimasMAX, which enhance treatment options. Morpheus8 has gained significant popularity, with over 2.5 million procedures performed globally.
Read more →INMDInMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is the first aesthetic company to officially partner with...
InMode Ltd. has announced a partnership with P1 Offshore Racing, sponsoring female driver Victoria Rand. This collaboration marks a significant milestone in motorsports, highlighting InMode's commitment to empowering women. Rand, an accomplished racer, aims to inspire confidence among women while competing in the Morpheus8 Offshore Race Team. The partnership reflects InMode's innovative spirit and dedication to breaking boundaries.
Read more →INMDInMode to Present at Upcoming Investor Conferences and Events InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor ...
InMode Ltd. has announced its participation in several upcoming investor conferences in November and December. Key presentations will be made by CEO Moshe Mizrahy and CFO Yair Malca at events in London and New York. These conferences aim to highlight InMode's innovative medical technologies and engage with potential investors.
Read more →INMD▼ -7.4%on this news
InMode Files Patent Infringement Complaint Against BTL Industries, Inc. (d/b/a BTL Aesthetics) InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced that it filed a patent infringement complaint in...
InMode Ltd. has filed a patent infringement complaint against BTL Industries in California, alleging that BTL's UltraFemme 360 and EmFemme 360 products infringe on its U.S. Patent No. 8,961,511. The company emphasizes its dedication to developing minimally invasive RF technologies and protecting its intellectual property. InMode aims to grow shareholder value through its innovative medical technologies.
Read more →INMD▼ -20%on this newsshared move
InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. has announced its preliminary financial results for Q3 2023, expecting revenues between $122.8 million and $123.0 million. The company has lowered its full-year revenue guidance to a range of $500 million to $510 million, citing economic challenges and seasonal sales fluctuations. A conference call is scheduled for November 2, 2023, to discuss these results.
Read more →INMDInMode to Present at Upcoming Investor Conferences and Events InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the...
InMode Ltd. announced its participation in several upcoming investor conferences in August, including the Canaccord Genuity's 43rd Annual Growth Conference and the UBS Med Device Conference. The presentations will feature key executives discussing the company's innovative medical technologies. Live webcasts will be available for some events, enhancing accessibility for investors.
Read more →INMDInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to announce the completion of a...
InMode Ltd. has completed the acquisition of all intellectual property assets from Viveve Medical Inc., enhancing its position in the women's health and wellness market. This acquisition, along with a licensing agreement with the University of California, strengthens InMode's patent portfolio and supports its long-term growth strategy. The company aims to continue developing innovative technologies for women's wellness.
Read more →INMD▲ +11%on this news
InMode Expects Second Quarter 2023 Revenue Between $135.7-$135.9M, Increases Full Year 2023 Guidance, Expects Revenues of $530-540M InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...
InMode Ltd. anticipates second quarter 2023 revenues between $135.7 million and $135.9 million, with an increase in full-year guidance to $530 million to $540 million. The company will release its financial results on July 27, 2023, and will host a conference call to discuss these results. Non-GAAP earnings per diluted share for Q2 are expected to be between $0.70 and $0.71.
Read more →INMDTavor Building, Sha'ar Yokneam, P.O.
Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel You are cordially invited to attend an annual general meeting (the "Meeting") of the shareholders of InMode Ltd. (the "Company"), to be held on Monday, April 4, 2022, beginning at 17:00, Israel time, at the of
Read more →INMDInMode Reports Third Quarter 2019 Record Revenue of $40 Million; Reflects Growth of 57% Year-Over-Year; Net Income Increased 87% to $16.2 Million
InMode Reports Third Quarter 2019 Record Revenue of $40 Million; Reflects Growth of 57% Year-Over-Year; Net Income Increased 87% to $16.2 Million YOKNEAM, Israel, November 5, 2019 /PRNewswire/-- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative med
Read more →INMDInMode Reports Second Quarter 2019 Financial Results; Record Quarterly Revenue of $38.8 million Reflects Growth of 55% Over Prior Year Net Income Increased 109% Over Prior Year to $15.8 million InMode Completed a Success
Second Quarter 2019 Financial Results; Record Quarterly Revenue of $38.8 million Reflects Growth of 55% Over Prior Year Increased 109% Over Prior Year to $15.8 million a Successful Initial Public Offering with Gross Proceeds of $70 million LAKE FOREST, Calif., August 13, 2019
Read more →INMDFINAL InMode Ltd. Announces Closing of Initial Public Offering
InMode Ltd. Announces Closing of Initial LAKE FOREST, Calif., August 12, 2019 /PRNewswire/-- InMode Ltd. (Nasdaq:INMD) ("InMode") announced today the closing of its initial public offering of 5,000,000 ordinary shares at an initial public offering price of $14.00 per ordinary
Read more →Competitive Position
How INMD ranks across every disease it competes inCompetitive Position is a premium feature
See how INMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial